Ion Beam Applications SA (EBR:IBAB)

Market Cap	457.85M +43.5%
Revenue (ttm)	639.00M +7.1%
Net Income	24.61M +44.7%
EPS	0.80 +38.9%
Shares Out	29.09M
PE Ratio	19.70
Forward PE	19.50
Dividend	0.25 (1.59%)
Ex-Dividend Date	Jun 15, 2026

Volume	5,510
Open	15.46
Previous Close	15.44
Day's Range	15.40 - 15.76
52-Week Range	9.90 - 17.76
Beta	1.26
Analysts	Buy
Price Target	17.63 (+12.01%)
Earnings Date	Nov 26, 2026

About Ion Beam Applications

Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments, serious illnesses, and industrial applications in Belgium, the United States, China, Germany, and India. It operates through four segments, Clinical Proton Therapy; Clinical Dosimetry; IBA Technologies; and IBA Corporate. The company develops ConformalFLASH, a novel technique using the proton Bragg peak; DynamicARC, a technique that allows dynamic spot scanning irradiation and energy switching while the gantry is rotating; Proteus ONE, a compa...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1986
• Employees: 2,264
• Stock Exchange: Euronext Brussels
• Ticker Symbol: IBAB

Financial Performance

In 2025, Ion Beam Applications's revenue was 620.18 million, an increase of 24.49% compared to the previous year's 498.16 million. Earnings were 12.73 million, an increase of 37.59%.

Analyst Summary

According to 4 analysts, the average rating for IBAB stock is "Buy." The 12-month stock price target is €17.63, which is an increase of 12.01% from the latest price.

Price Target

€17.63

(12.01% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error